Herantis Pharma Plc's (the "Company") Extraordinary General Meeting was held on Friday 17 November 2023 as a hybrid meeting in accordance with chapter 5, section 16, subsection 2 of the Finnish Companies Act. As an alternative to participating in the General Meeting at the meeting place, shareholders had the opportunity to fully exercise their rights during the meeting by remote connection. The Extraordinary General Meeting decided upon the following:

Authorization of the Board of Directors to decide on issuing shares

The Extraordinary General Meeting resolved to authorize the Board of Directors to decide on issuing shares as follows:

The shares issued under the authorization may be new shares or treasury shares. Under the authorization, a maximum of 5,082,000 shares may be issued which corresponds to approximately 30 percent of all the shares issued by the Company. The shares may be issued in one or more tranches.

The Board of Directors is authorized to resolve on all other terms and conditions of the share issue. The share issue may be directed, i.e., deviate from the pre-emptive subscription right of shareholders, provided that there is a weighty financial reason.

The proposed authorization does not invalidate any earlier authorizations entitling the Board of Directors to decide on share issues or issues of special rights entitling to shares.

The authorization is valid until the close of next Annual General Meeting, however no longer than until 30 June 2024.

Amendment of the Articles of Association

The Extraordinary General Meeting resolved on amending the Articles of Association of the Company so that that the Board of Directors is permitted to convene General Meetings of Shareholders as virtual or hybrid meetings in accordance with Chapter 5, Section 16, Subsections 2 and 3 of the Finnish Companies Act.

General Meeting minutes

The minutes of the General Meeting will be made available on the Company's website at https://herantis.com/investors/general-meetings/ by 1 December 2023 at the latest.